司美格鲁肽2.0 mg与度拉糖肽3.0 mg及4.5 mg的间接治疗比较:多水平网络Meta回归分析
本研究采用多水平网络Meta回归,对司美格鲁肽2.0 mg与度拉糖肽3.0 mg及4.5 mg在2型糖尿病患者中降低糖化血红蛋白(HbA1c)和体重的作用进行间接治疗比较(ITC)。结果显示,司美格鲁肽2.0 mg较度拉糖肽3.0 mg和4.5 mg显著降低HbA1c和体重,且达到HbA1c<7.0%的比值比在司美格鲁肽2.0 mg对度拉糖肽3.0 mg比较中显著,而对4.5 mg比较未达显著。
要点
- 司美格鲁肽2.0 mg较度拉糖肽3.0 mg和4.5 mg显著降低HbA1c,估计治疗差异分别为-0.44%点和-0.28%点。
- 司美格鲁肽2.0 mg较度拉糖肽3.0 mg和4.5 mg显著降低体重,估计治疗差异分别为-3.29 kg和-2.57 kg。
- 达到HbA1c<7.0%的比值比:司美格鲁肽2.0 mg对度拉糖肽3.0 mg为2.23(95% CrI 1.15-3.90),对度拉糖肽4.5 mg为1.58(95% CrI 0.82-2.78),后者未达显著。
核心结论
- 本间接治疗比较显示,司美格鲁肽2.0 mg较度拉糖肽3.0 mg和4.5 mg从基线显著降低HbA1c和体重。
- 研究结果在随机头对头研究可及之前提供了重要的比较有效性信息。
研究设计与样本
- 基于多水平网络Meta回归的间接治疗比较。
- 证据网络连接了度拉糖肽11试验的已发表结果与SUSTAIN及SUSTAIN 7试验的个体患者数据。
主要发现
- 司美格鲁肽2.0 mg较度拉糖肽3.0 mg显著降低HbA1c,估计治疗差异为-0.44%点(95% CrI -0.68至-0.19)。
- 司美格鲁肽2.0 mg较度拉糖肽4.5 mg显著降低HbA1c,估计治疗差异为-0.28%点(95% CrI -0.52至-0.03)。
- 司美格鲁肽2.0 mg较度拉糖肽3.0 mg显著降低体重,估计治疗差异为-3.29 kg(95% CrI -4.62至-1.96)。
- 司美格鲁肽2.0 mg较度拉糖肽4.5 mg显著降低体重,估计治疗差异为-2.57 kg(95% CrI -3.90至-1.24)。
- 达到HbA1c<7.0%的比值比:司美格鲁肽2.0 mg对度拉糖肽3.0 mg为2.23(95% CrI 1.15-3.90),对度拉糖肽4.5 mg为1.58(95% CrI 0.82-2.78),后者未达显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Currently, no head-to-head data are available comparing semaglutide 2.0 mg with dulaglutide 3.0 mg or 4.5 mg. We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes. MATERIALS AND METHODS: Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN) and SUSTAIN 7 trials. RESULTS: Semaglutide 2.0 mg significantly reduced HbA1c vs dulaglutide 3.0 mg and 4.5 mg, with estimated treatment differences (ETDs) of -0.44% points (95% credible interval [CrI], -0.68 to -0.19) and -0.28% points (95% CrI, -0.52 to -0.03), respectively. Semaglutide 2.0 mg also significantly reduced body weight vs dulaglutide 3.0 mg and 4.5 mg with ETDs of -3.29 kg (95% CrI, -4.62 to -1.96) and -2.57 kg (95% CrI, -3.90 to -1.24), respectively. Odds of achieving HbA1c < 7.0% were significantly greater for semaglutide 2.0 vs dulaglutide 3.0 mg (odds ratio [OR]: 2.23 [95% CrI, 1.15-3.90]), whereas this did not reach significance for semaglutide 2.0 mg vs dulaglutide 4.5 mg (OR: 1.58 [95% CrI, 0.82-2.78]). Sensitivity analyses supported the main analysis findings. CONCLUSIONS: This ITC demonstrated significantly greater reductions from baseline in HbA1c and body weight with semaglutide 2.0 mg vs dulaglutide 3.0 mg and 4.5 mg. The findings of this study provide important comparative effectiveness information until randomized head-to-head studies become available.
引用
- Lingvay I, Bauer R, Baker-Knight J, et al. An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. J Clin Endocrinol Metab. 2022. PMID: 34922383. doi:10.1210/clinem/dgab905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。